Strona glówna
•
FAQ
•
Szukaj
•
Użytkownicy
•
Grupy
•
Galerie
•
Rejestracja
•
Profil
•
Zaloguj się, by sprawdzić wiadomości
•
Zaloguj
Forum Forum MESA !! Strona Główna
->
Sędziowie
Napisz odpowiedź
Użytkownik
Temat
Treść wiadomości
Emotikony
Więcej Ikon
Kolor:
Domyślny
Ciemnoczerwony
Czerwony
Pomarańćzowy
Brązowy
Żółty
Zielony
Oliwkowy
Błękitny
Niebieski
Ciemnoniebieski
Purpurowy
Fioletowy
Biały
Czarny
Rozmiar:
Minimalny
Mały
Normalny
Duży
Ogromny
Zamknij Tagi
Opcje
HTML:
TAK
BBCode
:
TAK
Uśmieszki:
TAK
Wyłącz HTML w tym poście
Wyłącz BBCode w tym poście
Wyłącz Uśmieszki w tym poście
Kod potwierdzający: *
Wszystkie czasy w strefie EET (Europa)
Skocz do:
Wybierz forum
Nabór do ZESPÓŁ Forum MESA
----------------
Nabór
MESA - DRUŻYNY
----------------
GKS Bełchatów
Cracovia Kraków
Dyskobolia Grodzisk Wielkopolski
Górnik Zabrze
Jagiellonia Białystok
Korona Kielce
Lech Poznań
Legia Warszawa
ŁKS Łódź
Odra Wodzisław Śląski
Polonia Bytom
Ruch Chorzów
Wisła Kraków
Zagłębie Lubin
Zagłębie Sosnowiec
MESA - OGÓLNIE
----------------
Regulamin
Terminarz
Sędziowie
Wyniki
DLA KIBICA
----------------
Typer
Rozrywka
Sonda
INNE
----------------
Hydepark
Reklama
PARTNERZY
----------------
Parnerzy w reklamie i realizacji projektu !!
Przegląd tematu
Autor
Wiadomość
e707004304
Wysłany: Czw 19:31, 28 Kwi 2011
Temat postu: Short-term triple therapy for Hp -positive duodena
Short-term triple therapy for Hp-positive duodenal ulcer efficacy
Key words short-term triple therapy for duodenal ulcer Hp gastric acid, pepsin digestion and Helicobacter pylori (Hp ) infection is the most important risk factors of peptic ulcer, inhibit gastric acid secretion and eradication of Hp the treatment of peptic ulcer and prevention of ulcer recurrence major initiatives. 4 weeks of conventional therapy, the proton pump inhibitor (PPI) and the combination of amoxicillin and clarithromycin 1 week to continue PPI 3 weeks, and omeprazole as the PPI representative of drugs, the treatment of peptic ulcer has been recognized. This study aimed to investigate the short-term esomeprazole triple therapy for Hp-positive duodenal ulcer. 1 clinical data 1.1 General information on the inclusion criteria: age ≥ 18 years, endoscopy confirmed active duodenal ulcer (ulcer diameter of 3 ~ 20mm, 1 ~ 2 个), Hp testing positive (rapid urease test strongly positive). Exclusion criteria: age <18 years old, complex ulcer, pyloric obstruction or a combination of active bleeding, liver and kidney with severe heart and lung disease, are taking non-steroidal drugs, 1 month oral administration of anti-Hp used drugs, penicillin allergy, pregnancy or lactating women, esophagus, stomach, duodenum surgery, cancer and alcoholism. Select January 2004 to December 2005 60 cases of duodenal ulcer eligible, randomly divided into study group and treatment group, 30 cases in each. Basic differences between the two groups were not significant, both in the gastric mucosa of Endoscopic Biopsy 2 to 3, by rapid urease test, 3d medication started within 6 weeks, repeated endoscopy and urease breath test investigation (14C- UBT), measured values <100dpm> 50% reduction in the number or ulcers; invalid: ulcer size reduction or no change and increase. Healing rate of the first two terms, the first three terms efficient. Gastrointestinal symptoms rating: none (asymptomatic feeling); mild (aware of symptoms, but does not affect the normal activities); moderate (clearly does not affect the normal life); severe (loss of function, inability to carry out normal activities) . Remission after treatment for more than a relief of symptoms, the cure for the symptoms disappeared, improved to alleviate the symptoms, not invalid as to reduce the symptoms. 1.4 Application of SPSS 10.0 statistical software, data using χ2 test. To P <0.05 as significant difference. Were not lost into the statistics. 2 results of 2 patients in each group lost to follow-up rate of 93.3%. Ulcer healing rate study group 89.3% (25/2
, control group 85.7% (24/2
, the difference was not significant; ulcer study group was 92.9% efficient (26/2
, control group 92.9% (26/2
the difference was not statistically significant; Hp eradication rates of group 92.9% (26/2
, control group 89.3% (25/2
, the difference was not significant. Treatment of gastrointestinal symptoms after 1 week of evaluation, two groups of patients with abdominal pain, back acid and heartburn and other symptoms were in remission after medication 7d, respectively, on the incidence of abdominal pain before treatment of 100% and 92.9% to 7.1% and 10.7% , acid reflux rates were decreased from 53.6% and 57.1% to 10.7% and 7.1%, the incidence of heartburn before treatment respectively 67.9% and 71.4% dropped to 0, no significant difference between two groups.
fora.pl
- załóż własne forum dyskusyjne za darmo
Theme
FrayCan
created by
spleen
&
Download
Powered by
phpBB
© 2001, 2005 phpBB Group
Regulamin